Undifferentiated carcinoma of nasopharynx
diseaseOn this page
Also known as lymphoepithelioma of nasopharynxlymphoepithelioma of the nasopharynxnasopharyngeal lymphoepitheliomanasopharyngeal nonkeratinizing undifferentiated carcinomanasopharyngeal undifferentiated carcinomanasopharynx undifferentiated carcinomaundifferentiated carcinoma of the nasopharynxundifferentiated nasopharyngeal throat cancer
Summary
Undifferentiated carcinoma of nasopharynx (MONDO:0021537) is a cancer and 22 clinical trials. Top therapeutic interventions include cisplatin, amifostine, and erlotinib hydrochloride. A subtype of undifferentiated carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 22
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | undifferentiated carcinoma of nasopharynx |
| Mondo ID | MONDO:0021537 |
| ICD-11 | 584112926 |
| NCIT | C8023 |
| SNOMED CT | 422541001 |
| UMLS | C0279748 |
| MedGen | 124650 |
| GARD | 0025334 |
| Anatomy (UBERON) | UBERON:0001728 |
| Is cancer (heuristic) | yes |
Also known as: lymphoepithelioma of nasopharynx · lymphoepithelioma of the nasopharynx · nasopharyngeal lymphoepithelioma · nasopharyngeal nonkeratinizing undifferentiated carcinoma · nasopharyngeal undifferentiated carcinoma · nasopharynx undifferentiated carcinoma · undifferentiated carcinoma of the nasopharynx · undifferentiated nasopharyngeal throat cancer
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › undifferentiated carcinoma › undifferentiated carcinoma of nasopharynx
Related subtypes (13): nut midline carcinoma, endometrial undifferentiated carcinoma, salivary gland large cell carcinoma, sinonasal undifferentiated carcinoma, thymic undifferentiated carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, undifferentiated gallbladder carcinoma, undifferentiated ovarian carcinoma, undifferentiated pancreatic carcinoma, undifferentiated carcinoma of the corpus uteri, undifferentiated carcinoma of esophagus, undifferentiated carcinoma of stomach, undifferentiated carcinoma of liver and intrahepatic biliary tract
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 22.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 8 |
| PHASE2 | 7 |
| Not specified | 3 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00274937 | PHASE3 | COMPLETED | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer |
| NCT04458909 | PHASE3 | TERMINATED | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer |
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT00101348 | PHASE1/PHASE2 | COMPLETED | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer |
| NCT00408694 | PHASE2 | COMPLETED | Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer |
| NCT00454142 | PHASE2 | COMPLETED | Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer |
| NCT00492089 | PHASE2 | COMPLETED | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer |
| NCT00896181 | PHASE2 | COMPLETED | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) |
| NCT01806675 | PHASE1/PHASE2 | COMPLETED | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy |
| NCT02123511 | PHASE2 | COMPLETED | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy |
| NCT02794077 | PHASE2 | COMPLETED | Cyclophosphamide for Nasopharyngeal Carcinoma |
| NCT00336063 | PHASE1 | ACTIVE_NOT_RECRUITING | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma |
| NCT00023959 | PHASE1 | COMPLETED | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer |
| NCT00030498 | PHASE1 | COMPLETED | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
| NCT00031681 | PHASE1 | COMPLETED | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) |
| NCT00089362 | PHASE1 | COMPLETED | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors |
| NCT00397384 | PHASE1 | COMPLETED | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer |
| NCT00470496 | PHASE1 | COMPLETED | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer |
| NCT01637194 | PHASE1 | COMPLETED | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer |
| NCT00068497 | Not specified | COMPLETED | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer |
| NCT01155609 | Not specified | COMPLETED | L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer |
| NCT01254734 | Not specified | TERMINATED | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 4 |
| AMIFOSTINE | 4 | 1 |
| ERLOTINIB HYDROCHLORIDE | 4 | 1 |
| PAZOPANIB HYDROCHLORIDE | 4 | 1 |
| HPPH | 2 | 1 |
| LYSINE | 2 | 1 |
| UCN-01 | 2 | 1 |
| ALVESPIMYCIN HYDROCHLORIDE | 1 | 1 |
| CHEMBL1236539 | 0 | 1 |
Related Atlas pages
- Drugs: Cisplatin, Amifostine, Erlotinib, Pazopanib